Literature DB >> 19394140

Lumican core protein inhibits melanoma cell migration via alterations of focal adhesion complexes.

Stéphane Brézillon1, Agata Radwanska, Cedric Zeltz, Andrzej Malkowski, Dominique Ploton, Hélène Bobichon, Corinne Perreau, Maria Malicka-Blaszkiewicz, François-Xavier Maquart, Yanusz Wegrowski.   

Abstract

Lumican is a small leucine-rich proteoglycan (SLRP) of the extracellular matrix (ECM) with anti-tumor activity. We recently demonstrated that lumican inhibits the migration of melanoma cells and identified beta1 integrin as mediator of this effect [M.F. D'Onofrio, S. Brézillon, T. Baranek, C. Perreau, P.J. Roughley, F.X. Maquart, Y. Wegrowski, Identification of beta1 integrin as mediator of melanoma cell adhesion to lumican, Biochem. Biophys. Res. Commun. 365 (2008) 266-272]. The aim of the present work was to study beta1 integrin, focal adhesion complexes, actin distribution and expression in the presence of lumican substratum in comparison to type I collagen or fibronectin substrata in A375 human melanoma cells. The protein distribution was investigated by immunocytochemistry and confocal microscopy. In parallel, their expression was evaluated by Western immunoblotting and Real-time Reverse Transcription-PCR analyses. The interaction of melanoma cells with the lumican substratum resulted in heterogeneous distribution of beta1 integrin on cell membrane after 24h of seeding. Concomitantly, a reorganization of actin stress fibers and a significant decrease in vinculin immunostaining at focal adhesion complexes were observed. No alteration of the expression was detected at protein and mRNA levels. However, a cytosolic accumulation of vinculin focal adhesion protein was observed on lumican substratum by confocal microscopy. Moreover, vinculin expression was significantly increased in cytosolic fractions in comparison to cells seeded on type I collagen or fibronectin substrata. Our results suggest that lumican induces an alteration of the link between actin filaments and beta1 integrin, characterized by a cytosolic accumulation of vinculin focal adhesion protein, which could lead to a destabilization of focal adhesion complexes. In addition, focal adhesion kinase phosphorylated at tyrosine-397 (pFAK) was significantly decreased. Therefore, the cytoskeleton remodeling and the decreased pFAK phosphorylation induced by lumican in melanoma cells might explain, at least in part, the anti-invasive effect of this SLRP.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19394140     DOI: 10.1016/j.canlet.2009.03.032

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  28 in total

Review 1.  Proteoglycomics: recent progress and future challenges.

Authors:  Mellisa Ly; Tatiana N Laremore; Robert J Linhardt
Journal:  OMICS       Date:  2010-08

2.  Lysine methylation of progesterone receptor at activation function 1 regulates both ligand-independent activity and ligand sensitivity of the receptor.

Authors:  Hwa Hwa Chung; Siu Kwan Sze; Amanda Rui En Woo; Yang Sun; Kae Hwan Sim; Xue Ming Dong; Valerie C-L Lin
Journal:  J Biol Chem       Date:  2014-01-10       Impact factor: 5.157

3.  Leukemia stem cells promote chemoresistance by inducing downregulation of lumican in mesenchymal stem cells.

Authors:  Zhen Yu; Lin Liu; Qiang Shu; Dong Li; Ran Wang
Journal:  Oncol Lett       Date:  2019-08-22       Impact factor: 2.967

4.  Extracellular lumican inhibits pancreatic cancer cell growth and is associated with prolonged survival after surgery.

Authors:  Xinqun Li; Mark A Truty; Ya'an Kang; Xavier Chopin-Laly; Ran Zhang; David Roife; Deyali Chatterjee; E Lin; Ryan M Thomas; Huamin Wang; Matthew H Katz; Jason B Fleming
Journal:  Clin Cancer Res       Date:  2014-10-21       Impact factor: 12.531

Review 5.  Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans.

Authors:  Renato V Iozzo; Liliana Schaefer
Journal:  FEBS J       Date:  2010-08-31       Impact factor: 5.542

6.  Lumican reduces tumor growth via induction of fas-mediated endothelial cell apoptosis.

Authors:  Kent E Williams; Logan A Fulford; Allan R Albig
Journal:  Cancer Microenviron       Date:  2010-11-18

Review 7.  Small leucine-rich repeat proteoglycans in corneal inflammation and wound healing.

Authors:  Jihane Frikeche; George Maiti; Shukti Chakravarti
Journal:  Exp Eye Res       Date:  2016-08-26       Impact factor: 3.467

8.  Lumican exhibits anti-angiogenic activity in a context specific manner.

Authors:  Bikram Sharma; Megan D Ramus; Christopher T Kirkwood; Emma E Sperry; Pao-Hsien Chu; Winston W Kao; Allan R Albig
Journal:  Cancer Microenviron       Date:  2013-06-18

9.  Lumican expression, localization and antitumor activity in prostate cancer.

Authors:  Vivien J Coulson-Thomas; Yvette M Coulson-Thomas; Tarsis F Gesteira; Claudia A Andrade de Paula; Celia R W Carneiro; Valdemar Ortiz; Leny Toma; Winston W-Y Kao; Helena B Nader
Journal:  Exp Cell Res       Date:  2013-02-08       Impact factor: 3.905

10.  Extracellular matrix lumican promotes bacterial phagocytosis, and Lum-/- mice show increased Pseudomonas aeruginosa lung infection severity.

Authors:  HanJuan Shao; Seakwoo Lee; Sherri Gae-Scott; Chiaki Nakata; Shoujun Chen; Abdel R Hamad; Shukti Chakravarti
Journal:  J Biol Chem       Date:  2012-08-03       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.